Business Context and Reporting Period
This Form 8-K Current Report from DarioHealth Corp. covers events occurring on November 29, 2018, specifically the results of the Company's 2018 Special Meeting of Stockholders. The filing details corporate governance changes, equity plan amendments, and the approval of a private placement conversion.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
- Equity Incentive Plan Amendment: Stockholders approved an increase in the number of shares authorized for issuance under the Amended and Restated 2012 Equity Incentive Plan by 2,500,000 shares, raising the total from 5,373,000 to 7,873,000 shares.
- Bylaw Amendment: Stockholders approved an amendment to the Company's bylaws allowing for the removal of a director with or without cause by a majority vote. Previously, removal required a 66 2/3% vote and was limited to "for cause" scenarios.
- Private Placement Conversion: Stockholders approved the conversion of 1,890,257 shares of Series D Convertible Preferred Stock into 7,561,028 shares of common stock at a conversion price of $0.90 per share. This action was required to satisfy Nasdaq Listing Rule 5635(d).
Voting Results and Management Commentary
The filing provides the final voting results for three proposals at the Special Meeting:
- Proposal 1 (Private Placement): Approved with 17,312,460 votes For, 82,732 Against, and 65,475 Abstain. Note: 5,764,666 shares held by private placement investors were excluded from the vote count.
- Proposal 2 (Incentive Plan): Approved with 17,017,811 votes For, 213,387 Against, and 229,469 Abstain.
- Proposal 3 (Bylaw Amendment): Approved with 17,414,407 votes For, 40,772 Against, and 5,488 Abstain, meeting the required 66 2/3% threshold.
The filing does not contain forward-looking guidance, risk factors, or management commentary beyond the factual reporting of these approvals.
Investor Verification Checklist
- Verify the impact of the 2,500,000 share increase on future dilution and the 2012 Equity Incentive Plan.
- Confirm the effective date and specific terms of the Series D Preferred Stock conversion into common stock.
- Review the full text of the Bylaw Amendment (Exhibit 3.1) to understand the new director removal procedures.
- Check subsequent filings for the actual issuance of the converted common stock shares.